A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

PURPOSE: Vandetanib, a tyrosine kinase inhibitor of KDR (VEGFR2), EGFR, and RET, may enhance sensitivity to chemotherapy and radiation. We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Lee, Eudocia Q., Kaley, Thomas J., Duda, Dan G., Schiff, David, Lassman, Andrew B., Wong, Eric T., Mikkelsen, Tom, Purow, Benjamin W., Muzikansky, Alona, Ancukiewicz, Marek, Huse, Jason T., Ramkissoon, Shakti, Drappatz, Jan, Norden, Andrew D., Beroukhim, Rameen, Weiss, Stephanie E., Alexander, Brian M., McCluskey, Christine S., Gerard, Mary, Smith, Katrina H., Jain, Rakesh K., Batchelor, Tracy T., Ligon, Keith L., Wen, Patrick Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4790106/
https://ncbi.nlm.nih.gov/pubmed/25910950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados